Peripheral Neuropathy Trial, Recruiting NCT07019259 Sponsor: Yale University Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT07019259
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were diagnosed with cancer before the age of 21.
  • People who are currently aged 5 years or older (this lower age limit exists because the measurement tools used in this trial have only been tested and proven reliable for this age group).
  • People who were treated with certain chemotherapy drugs — specifically vinca alkaloids, platinum-based drugs, or other chemotherapy known to cause nerve damage.
  • People who have been assessed by a trained physical therapist and found to have chemotherapy-related nerve damage, based on a specific scoring system (the ped-mTNS for those under 18 at the time of assessment, or the mTNS for those aged 18 or older at the time of assessment).

Who may not be able to join:

  • People who are currently pregnant or breastfeeding, at the start of the trial or at any point during it.
  • People who are unable to sit still for at least 15 minutes.
  • People who had a nerve damage condition diagnosed before their cancer treatment began.
  • People who currently have an active cancer diagnosis or a cancerous skin lesion.
  • People who had a tumour in the brain or central nervous system (because the measurement tools used in this trial have not been validated for this group).
  • People who have a cancer lesion, an open wound, or any other condition in the area to be treated that could potentially be made worse by the device used in this trial, whether used correctly or incorrectly.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rozalyn Rodwin, MD, Yale University

Phone: 203-785-2407

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
30 June 2025
Est. completion
1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility of light therapy protocol

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov